Bivalacqua, Trinity J., Hunter C. Champion, Mrugeshkumar K. Shah, Bracken J. De Witt, Edward W. Inscho, and Philip J. Kadowitz. Comparative responses to ␣,␤-methylene-ATP in cat pulmonary, mesenteric, and hindquarter vascular beds. J Appl Physiol 93: 1287-1295, 2002; 10.1152/japplphysiol.00262.2002.-Responses to the P2X-purinoceptor agonist ␣,␤-methylene-ATP (␣,␤-MeATP) were investigated in the pulmonary, hindquarter, and mesenteric vascular beds in the cat. Under constant-flow conditions, injections of ␣,␤-MeATP caused dose-related increases in perfusion pressure in the pulmonary and hindquarter beds and a biphasic response in the mesenteric circulation. In the pulmonary vascular bed, the order of potency was ␣,␤-MeATP Ͼ U-46619 Ͼ angiotensin II, whereas, in the hindquarters, the order of potency was angiotensin II Ͼ U-46619 Ͼ ␣,␤-MeATP. The order of potency was similar in the hindquarter and mesenteric beds when the pressor component of the response to ␣,␤-MeATP was compared with responses to angiotensin II and U-46619. The P2X-receptor antagonist pyridoxal-phosphate-6-azophenyl-2Ј,4Ј-disulfonic acid attenuated the pressor response to ␣,␤-MeATP in the hindquarter circulation and the pressor component in the mesenteric vascular bed. Pressor responses to ␣,␤-MeATP were not altered by cyclooxygenase, ␣-adrenergic, or angiotensin AT 1 antagonists. These data show that ␣,␤-MeATP has potent pressor activity in the pulmonary circulation, where it was 100-fold more potent than angiotensin II. In contrast, ␣,␤-MeATP had modest pressor activity in the systemic bed, where it was 1,000-fold less potent than angiotensin II. These data suggest that responses to ␣,␤-MeATP are dependent on the vascular bed studied and may be dependent on the density of P2X receptors in the vascular bed.
THE CARDIOVASCULAR EFFECTS of ATP were first reported by Drury and Szent-Gyorgyi in 1929 (12) , and, since that early study, a great deal of information has been accumulated about responses to extracellular adenine nucleotides. In 1978, Burnstock (5) proposed that ATP acts on a distinct class of receptors called P2 receptors, whereas adenosine acts on P 1 receptors. Subsequently, based on the rank order of activity of agonists on vascular and nonvascular smooth muscle, the P2 receptor was subdivided into P2X-and P2Y-receptor subfamilies (14, 25) . P2X receptors are thought to be ligand-gated cation channels permeable to Na ϩ , K ϩ , and Ca 2ϩ (13-18, 23, 25, 31, 33) . There are seven cloned P2X receptors (1, 13, 23, 25) . P2X 1 receptors are located on vascular smooth muscle, and activation of P2X receptors most often causes vasoconstriction (15, 29) . P2Y receptors are G-coupled receptors located on the endothelium and on vascular smooth muscle cells (4, 13, 25) . Activation of endothelial P2Y receptors has been shown to lead to vascular smooth muscle relaxation (7, 16) . The distribution of P2X and P2Y receptors may determine the properties of the response to a P2-receptor agonist in different regional vascular beds.
␣,␤-Methylene ATP (␣,␤-MeATP) is a degradationresistant ATP analog that has potent vasoconstrictor activity in the pulmonary vascular bed (10, 21, 22, 27) . Pressor responses to ␣,␤-MeATP in the pulmonary vascular bed are inhibited by pyridoxal-phosphate-6-azophenyl-2Ј,4Ј-disulfonic acid (PPADS), and radioligand studies show that P2X receptors are localized in large and small pulmonary arteries and veins (19, 22, 26) . Responses to ␣,␤-MeATP have been studied in rat tail arteries; femoral, cerebral, and renal arteries; the perfused rat mesenteric vascular bed; and saphenous veins (3, 9, 24, 28, 30, 34) . P2X-receptor antagonists have been developed, and PPADS has been shown to be an antagonist at the endogenous P2X 1 receptor and on recombinant P2X 1 , P2X 3 , and P2X 5 receptors (19, 24, 26, 35) .
Although PPADS has been shown to selectively antagonize responses to ␣,␤-MeATP in the feline pulmonary vascular bed, little if anything is known about responses to ␣,␤-MeATP and the effects of PPADS in the systemic vascular bed in the cat. The purpose of the present study was to compare responses to ␣,␤-MeATP in the pulmonary, mesenteric, and hindquarter vascular beds and to investigate the effects of PPADS on systemic vascular responses to the P2X agonist.
Supplemental doses of pentobarbital were given, as needed, to maintain a uniform level of anesthesia. The trachea was cannulated, and the animals either breathed spontaneously or were ventilated with a Harvard model 607 ventilator at a volume of 40-60 ml at 15-22 breaths/min. An external jugular vein was catheterized for the intravenous (iv) administration of drugs, and a carotid artery was catheterized for the measurement of systemic arterial pressure.
Mesenteric preparation. For constant-flow perfusion of the mesenteric vascular bed, the superior mesenteric artery was approached through a midline abdominal incision and carefully cleared of surrounding tissue. The mesenteric vascular bed was denervated by ligating and cutting the perivascular nerves to the small intestine as they course along the superior mesenteric artery. After the administration of heparin sodium (1,000 U/kg), the femoral artery was cannulated and connected to the inlet side of the perfusion circuit. The outlet side of the perfusion circuit was connected to a catheter inserted into the superior mesenteric artery. Blood flow to the small intestine was maintained constant with a Sigmamotor model T-8 perfusion pump. Superior mesenteric arterial perfusion pressure was measured by way of a lateral tap in the perfusion circuit located between the pump and the outlet side of the perfusion circuit. Superior mesenteric arterial perfusion pressure and systemic arterial pressure were measured with Statham P23 pressure transducers and were recorded on a Grass model 7 polygraph. Mean pressures were derived by electronic averaging, and the perfusion rate was set so that superior mesenteric arterial perfusion pressure approximated systemic arterial pressure and was not changed during the experiment. The flow rate was determined by timed collection and ranged from 26-36 ml/min. The agonists used during these experiments were injected in small volumes (30 and 100 l) and, in random fashion, directly into the superior mesenteric artery perfusion circuit, distal to the pump, as described previously (8) .
Hindquarter preparation. For perfusion of the hindquarter vascular bed, a 3-to 4-cm segment of distal aorta was exposed through a ventral midline incision and was cleared of surrounding connective tissue by blunt dissection. After administration of heparin sodium (1,000 U/kg iv), the abdominal aorta was ligated, and catheters were inserted into the aorta proximal and distal to the ligature. Branches of the aorta distal to the origin of the external iliac arteries were ligated to restrict blood flow to the hindquarters. Blood was withdrawn from the proximal catheter and pumped at a constant flow rate with a Sigmamotor model T-8 pump into the distal aortic catheter. Hindquarter perfusion pressure and systemic arterial pressure were measured with Statham P23 transducers and were recorded on a Grass model 7 polygraph. Mean pressures were derived by electronic averaging, and the flow rate was set so that hindquarter perfusion pressure approximated systemic arterial pressure and was not changed during the experiment. The flow rate was determined by timed collection and ranged from 24 to 30 ml/min. Agonists were injected in small volumes and in a random sequence directly into the hindquarter perfusion circuit distal to the pump. The hindquarter vascular bed was denervated by ligating and cutting of the lumbar sympathetic chain ganglia between L3 and L4. These procedures have been described previously (2) .
Pulmonary preparation. For studies in the pulmonary vascular bed, the animals were positioned in the supine position on a fluoroscopic table. The trachea was intubated with a cuffed pediatric endotracheal tube, and the animals spontaneously breathed room air enriched with 100% O2. Systemic arterial pressure was measured from a catheter inserted into the aorta from a femoral artery, and iv injections were made into a catheter positioned in the inferior vena cava from a femoral vein. For perfusion of the left lower lung lobe, a triple-lumen, 28-cm, 6-Fr balloon perfusion catheter was passed, under fluoroscopic guidance, from an external jugular vein through the pulmonary artery to the left lower lung lobe. After the animals had been heparinized (1,000 U/kg iv), the lobar artery was vascularly isolated by distension of the balloon cuff on the perfusion catheter. The lobe was perfused with a perfusion pump (model 1210, Harvard Instruments) by way of the catheter lumen beyond the cuff with blood withdrawn from a femoral artery. The perfusion rate was adjusted so that lobar arterial perfusion pressure approximated mean pressure in the main pulmonary artery and was not changed thereafter. The flow rate ranged from 28 to 45 ml/min. Left atrial pressure was measured with a radiopaque 6-Fr double-lumen catheter passed transseptally into the left atrium. Mean vascular pressures, measured with Spectromed DTX Plus transducers, zeroed at right atrial level and were recorded on a Grass model 7 polygraph. These procedures have been described previously (10, 11) .
In the first set of experiments, responses to local injections of ␣,␤-MeATP were compared in the pulmonary, mesenteric, and hindquarter vascular beds under constant-flow conditions. Dose-response curves for ␣,␤-MeATP, the thromboxane mimic U-46619, and angiotensin II were compared in the three vascular beds, and doses of the agonists were compared on a nanomole basis to take molecular weight into account. In these experiments, doses of the agonists were randomized, and sufficient time was permitted between agonist injections to ensure that tachyphylaxis did not occur. Control doseresponse curves for ␣,␤-MeATP, angiotensin II, and U-46619 were similar or identical, indicating that tachyphylaxis did not occur in these experiments.
In the second set of experiments, the role of P2X-receptor activation in mediating responses to ␣,␤-MeATP was investigated in the mesenteric and hindquarter vascular beds. Responses to ␣,␤-MeATP were compared before and after administration of the P2X-receptor antagonist PPADS (15 mg/kg iv). Administration of PPADS did not significantly change systemic arterial, mesenteric, and hindquarter perfusion pressure.
In the third set of experiments, the role of adrenergic receptors in mediating responses to ␣,␤-MeATP was investigated in the mesenteric and hindquarter vascular beds. Responses to ␣,␤-MeATP were compared before and after administration of the ␣-adrenergic-receptor antagonist phentolamine (1 mg/kg iv), and in some experiments a doseresponse curve for ␣,␤-MeATP was obtained before and after administration of phentolamine. Phentolamine decreased mesenteric perfusion pressure from 132 Ϯ 7 to 101 Ϯ 8 mmHg and systemic arterial pressure from 123 Ϯ 7 to 103 Ϯ 6 mmHg and decreased hindquarters perfusion pressure from 117 Ϯ 11 to 92 Ϯ 8 mmHg and systemic arterial pressure from 133 Ϯ 15 to 107 Ϯ 17 mmHg.
In the fourth set of experiments, the role of AT1-receptor activation in mediating responses to ␣,␤-MeATP was investigated in the mesenteric and hindquarter vascular beds. Responses to ␣,␤-MeATP were compared before and after administration of the angiotensin AT1-receptor antagonists losartan (1 mg/kg iv) in the mesenteric vascular bed and candesartan (1 mg/kg iv) in the hindquarter vascular bed. The extent of AT1-receptor blockade was similar with losartan and candesartan, because responses to angiotensin II were reduced to a similar extent in both vascular beds, and, in additional experiments, losartan did not change the response to ␣,␤-MeATP in the hindquarter vascular bed. In some experiments, dose-response curves for ␣,␤-MeATP were compared before and after administration of the AT 1-receptor antagonists. Mesenteric and hindquarter perfusion pressures were not altered by losartan or candesartan.
In the fifth set of experiments, the role of cyclooxygenase product formation in modulating responses to ␣,␤-MeATP was investigated in the mesenteric and hindquarter vascular beds. Responses to ␣,␤-MeATP were compared before and after administration of the cyclooxygenase inhibitor sodium meclofenamate (2.5 mg/kg iv), and in some experiments doseresponse curves for ␣,␤-MeATP were obtained before and after administration of the cyclooxygenase inhibitor. Sodium meclofenamate did not alter mesenteric or hindquarter perfusion pressure.
Drugs. ␣,␤-MeATP, sodium meclofenamate, phentolamine, and angiotensin II (Sigma Chemical, St. Louis, MO) were dissolved in 0.9% NaCl solution. PPADS tetrasodium (Research Biochemicals International, Natick, MA) and losartan (Dupont-Merck, Wilmington, DE) were dissolved in 0.9% NaCl solution. U-46619 (Upjohn, Kalamazoo, MI) was dissolved in 100% ethanol at a concentration of 10 mg/ml and was diluted in 0.9% NaCl. BAY K 8644 (Miles, New Haven, CT) was dissolved in a 1:4 solution of cremophor EL and Tris and Tris ⅐ HCl (50 mM, pH 7.4). The resulting suspension was warmed, and polyethylene glycol and Tris (pH 7.4) were added to make a stock solution that was stored (0°C) in a brown bottle. Candesartan (Astra Zeneca) was dissolved in 1 N NaOH. Working solutions of all agonists were prepared on a frequent basis, stored in brown stoppered bottles, and kept on crushed ice during the experiment. Vehicles for the drugs used in these studies did not significantly alter baseline pressures or responses to the vasoactive agents. All agonists were injected directly into the perfusion circuit in small volumes in a random sequence, and sufficient time was permitted between injections for perfusion pressure to return to baseline values.
Statistical analysis. Responses were measured in absolute units (mmHg) and presented as means Ϯ SE. The data were analyzed by using a one-way analysis of variance and Scheffé's F-test with a Bonferroni/Dunn correction factor or paired t-test. A P value of Ͻ0.05 was used as the criterion for statistical significance.
RESULTS
Responses to ␣,␤-MeATP in the pulmonary, hindquarter, and mesenteric vascular beds. Local injections of ␣,␤-MeATP into the lobar and hindquarter perfusion circuits in the cat caused dose-related increases in perfusion pressure (Fig. 1, A and B) . In contrast, injections of ␣,␤-MeATP into the mesenteric perfusion circuit resulted in a biphasic response characterized by an initial increase in perfusion pressure followed by a secondary smaller decrease in perfusion pressure (Fig.  1C) . The time course of the changes in perfusion pressure in response to ␣,␤-MeATP in the pulmonary, hindquarter, and mesenteric vascular beds is compared in Fig. 2 . The increase in lobar arterial perfusion pressure in response to the 10-ng dose of ␣,␤-MeATP was rapid in onset, and pressure slowly returned toward the baseline value over a 350-s period (Fig. 2A) . The increase in hindquarter perfusion pressure in response to the 30-g dose of ␣,␤-MeATP was slow in onset and reached a peak ϳ50 s after injection. Perfusion pressure returned to the baseline value ϳ250 s after injection (Fig. 2B) . The increase in mesenteric perfusion pressure in response to the 30-g dose of ␣,␤-MeATP was rapid in onset and reached a peak in ϳ15 s. Perfusion pressure then rapidly returned toward the baseline and decreased below baseline value (Fig. 2C) . The secondary depressor response was slower in onset and decay (Fig. 2C) . The response to the 30-g dose of ␣,␤-MeATP in the mesenteric vascular bed lasted ϳ270 s (Fig. 2C) .
Responses to ␣,␤-MeATP were compared with responses to the thromboxane A 2 mimic U-46619 and to angiotensin II in the pulmonary, hindquarter, and mesenteric vascular beds of the cat, and these data are shown in Fig. 3 . In the pulmonary vascular bed, the order of potency was ␣,␤-MeATP Ͼ U-46619 Ͼ angiotensin II. The dose-response curve for ␣,␤-MeATP was ϳ0.5 log units to the left of the dose-response curve for U-46619 and ϳ1-1.5 log units to the left of the doseresponse curve for angiotensin II (Fig. 3A) . In the hindquarter vascular bed, the order of potency was angiotensin II Ͼ U-46619 Ͼ ␣,␤-MeATP. The doseresponse curve for ␣,␤-MeATP was ϳ2 log units to the right of the curve for U-46619 and 3 log units to the right of the curve for angiotensin II (Fig. 3B) . In the mesenteric vascular bed, the order of potency was angiotensin II Ͼ U-46619 Ͼ ␣,␤-MeATP. The pressor component of the dose-response curve for ␣,␤-MeATP was ϳ2 log units to the right of the curve for U-46619 and ϳ3 log units to the right of the curve for angiotensin II (Fig. 3C) .
Effect of PPADS.
The effect of the P2X-receptor antagonist PPADS on the response to ␣,␤-MeATP has been previously studied in the pulmonary vascular bed of the cat by using a similar procedure, and, in that study, PPADS (15 mg/kg iv) was found to attenuate the pressor response to the P2X-receptor agonist in a selective manner (22) . In the present study, the effects of PPADS in a dose of 15 mg/kg iv on responses to ␣,␤-MeATP were investigated in the mesenteric and hindquarter vascular beds, and these data are summarized in Figs. 4 and 5. After administration of PPADS, the vasoconstrictor component of the response to ␣,␤- MeATP was decreased significantly, and the dose-response curve for the purinergic agonist was shifted to the right in a parallel manner in the mesenteric vascular bed (Fig. 4) . After administration of PPADS, the magnitude of the secondary vasodilator component of the response to the 30-and 100-g doses of ␣,␤-MeATP was increased significantly in the mesenteric vascular bed (Fig. 4) . The duration of action of PPADS was short, and responses to ␣,␤-MeATP returned toward control value 60 min after administration of the antagonist (data not shown). The selectivity of the inhibitory effects of PPADS on responses to ␣,␤-MeATP was assessed, and, in a dose of 15 mg/kg iv, the purinergic antagonist did not alter vasoconstrictor responses to norepinephrine, BAY K 8644, and U-46619 in the mesenteric vascular bed (Fig. 4) .
After administration of PPADS (15 mg/kg iv), hindquarter vasoconstrictor responses to ␣,␤-MeATP were significantly reduced, and the dose-response curve for the purinergic agonist was shifted to the right in a parallel manner (Fig. 5) . In a manner similar to that observed in the mesenteric vascular bed, the duration of the inhibitory action of PPADS was short, and responses to ␣,␤-MeATP returned toward control value 60 min after administration of the antagonist (data not shown). PPADS did not alter responses to norepinephrine, BAY K 8644, or U-46619 in the hindquarter vascular bed (Fig. 5) .
Role of AT 1 and ␣-adrenergic receptors and the cyclooxygenase system. The role of angiotensin AT 1 and ␣-adrenergic receptors in mediating responses to ␣,␤-MeATP was investigated in the mesenteric and hindquarter vascular beds, and these data are summarized in Figs. 6 and 7. Responses to ␣,␤-MeATP were not altered by the AT 1 -receptor antagonist losartan in the mesenteric vascular bed or candesartan in the hindquarter vascular bed in a dose of the AT 1 antagonists (1 mg/kg iv) that significantly inhibited responses to angiotensin II (Fig. 6) . The AT 1 -receptor antagonists did not alter responses to U-46619 in both regional vascular beds (data not shown).
The role of ␣-adrenergic receptors in mediating responses to ␣,␤-MeATP was investigated in experiments with phentolamine (1 mg/kg iv) in the mesenteric and hindquarter vascular beds, and these data are summarized in Fig. 7 . After administration of phentolamine, responses to ␣,␤-MeATP were not altered at a time when vasoconstrictor responses to norepinephrine were decreased significantly (Fig. 7) . Responses to U-46619 were not changed after treatment with phentolamine (data not shown).
The role of cyclooxygenase product formation in modulating responses to ␣,␤-MeATP was investigated in the mesenteric and hindquarter vascular beds, and these data are summarized in Fig. 8 . After administra- tion of sodium meclofenamate (2.5 mg/kg iv), responses to ␣,␤-MeATP were not altered in the hindquarter and mesenteric vascular beds of the cat (Fig. 8) . The vasodilator response to the prostaglandin precursor arachidonic acid was decreased significantly after administration of the cyclooxygenase inhibitor (Fig. 8) . Vasodilator responses to acetylcholine were not changed in the mesenteric or hindquarter vascular bed after administration of the cyclooxygenase inhibitor (data not shown).
DISCUSSION
Results of the present study show that the selective P2X-receptor agonist ␣,␤-MeATP increases perfusion pressure in the pulmonary and hindquarter vascular beds and produces biphasic changes in perfusion pressure in the mesenteric vascular bed. Inasmuch as blood flow was maintained constant, the changes in perfusion pressure directly reflect changes in vascular resistance in the three vascular beds studied. Although vasoconstriction was observed in the pulmonary and hindquarter vascular beds and a biphasic response was observed in the mesenteric circulation, the response to ␣,␤-MeATP also differed with regard to relative pressor activity compared with the responses to the thromboxane A 2 mimic U-46619 and to angiotensin II in the pulmonary and systemic vascular beds. In the mesenteric vascular bed, analysis of the dose-response curve for the pressor component of the response to ␣,␤-MeATP showed that the purinergic agonist was 1,000-fold less potent than angiotensin II and 100-fold less potent than U-46619. In terms of relative vasoconstrictor activity and in the hindquarter vascular bed, ␣,␤-MeATP was 1,000-fold less potent than angiotensin II and 100-fold less potent than U-46619. In the pulmonary vascular bed, ␣,␤-MeATP was the most potent agonist and was 100-fold more potent than angiotensin II and 30-fold more potent than U-46619 in increasing pulmonary vascular resistance. The results of these comparative studies show marked differences in vasoconstrictor activity in the regional vascular response to the P2X agonist ␣,␤-MeATP compared with responses to angiotensin II and the thromboxane A 2 mimic U-46619. The present study demonstrates that ␣,␤-MeATP is one of the most potent vasoconstrictor agents in the pulmonary vascular bed while having modest vasoconstrictor activity in the systemic vascular bed. The reason for the marked difference in relative pressor activity is unknown but may reflect differences in the density of P2X receptors in each bed. The comparison of P2X-receptor density using radioligand techniques to quantify receptors in small arteries in three vascular beds would provide additional mechanistic information in the present study. The potent pressor response in the pulmonary circulation compared with U-46619 and angiotensin II suggests a potential role for P2X-receptor activation in pathophysiological conditions, such as chronic hypoxia, acute respiratory distress syndrome, and pulmonary hypertension. The role of P2X-receptor activation in pathophysiological conditions may be important, and information can be obtained by examining the effects of PPADS in experimental models of conditions, such as the acute respiratory distress syndrome.
The purinergic receptor subtype and mechanism by which ␣,␤-MeATP alters vascular resistance were investigated in the mesenteric and hindquarter vascular beds. The vasoconstrictor response to ␣,␤-MeATP in the hindquarter circulation and the vasoconstrictor component of the biphasic mesenteric response were attenuated by PPADS, a P2X-receptor antagonist (19, 25, 26, 35) . The dose-response curves for ␣,␤-MeATP were shifted to the right in a parallel manner in both beds, indicating that the antagonism was competitive. PPADS has been shown to block P2X 1 , P2X 2 , P2X 3 , P2X 5 , and P2Y 1 receptors; however, the P2X 1 receptor is the major P2X-receptor subtype on vascular smooth muscle (23, 25) . P2X 1 receptors usually mediate vasoconstriction, and the selectivity of the inhibitory effect of PPADS on the response to ␣,␤-MeATP was assessed by investigating the actions of the P2X-receptor antagonist on responses to agonists that change vascular resistance by various mechanisms (25, 29, 32) . The results of these studies show that PPADS did not alter vasoconstrictor responses to norepinephrine, BAY K 8644, or U-46619 in the mesenteric and hindquarter vascular beds. The results of these studies suggest that increases in mesenteric and hindquarter vascular resistance in response to ␣,␤-MeATP are mediated by the activation of P2X 1 receptors. These data are consistent with a previous report showing that ␣,␤-MeATP induces vasoconstriction in the cat intestine by activating P2X receptors (31) . It has also been reported that ␣,␤-MeATP causes dose-dependent vasoconstriction by activation of P2X 1 receptors in the isolated perfused pulmonary vascular bed of the rat, and these responses were blocked by PPADS (27) . Additionally, the distribution of P2X receptors in the cat lung has been studied by using autoradiographic techniques (22) . The results of these studies show that P2X receptors are expressed in high density in large and small pulmonary arteries, as well as in pulmonary veins (22) . In that study, with the use of a procedure similar to the technique used in the present study, pulmonary vasoconstrictor responses to ␣,␤-MeATP in the cat were attenuated in a selective manner by PPADS in a dose of 15 mg/kg iv and were not altered by cyclooxygenase inhibitors, ␣-adrenergic-receptor blocking agents, or histamine and serotonin blocking agents (22) . Responses to ␣,␤-MeATP have been studied in careful detail in the pulmonary vascular bed in the cat and, in a manner similar to that observed in the hindquarter and mesenteric vascular beds, appear to be mediated in a direct manner (10, 21, 22) .
The role of cyclooxygenase product release and activation of ␣-adrenergic or angiotensin AT 1 receptors in mediating or modulating responses to ␣,␤-MeATP was investigated in the mesenteric and hindquarter vascular beds. Responses to ␣,␤-MeATP were not altered by the cyclooxygenase inhibitor sodium meclofenamate in a dose that attenuated the response to the prostaglandin precursor arachidonic acid or by phentolamine in a dose that reduced the pressor response to norepinephrine. These results suggest that responses to ␣,␤-MeATP are not mediated by or modulated by the release of cyclooxygenase products or the activation of ␣-adrenergic receptors in the two vascular beds. The observation that mesenteric and hindquarter responses to ␣,␤-MeATP were not altered by losartan and candesartan in a dose that attenuated responses to angiotensin II suggests that activation of AT 1 receptors is also not involved in mediating responses to the purinergic agonist. Previous studies have shown the involvement of these mechanisms in mediating or in modulating responses to purinergic agonists in other organ systems (4, 6, 19, 20, 24) . The reason for the difference in the mechanism of action to ␣,␤-MeATP in these studies is unclear but may involve differences in the regional vascular bed or species studied.
In summary, results of the present study show that responses to the P2X-receptor agonist ␣,␤-MeATP differ in the three vascular beds studied in the cat. In the pulmonary vascular bed, ␣,␤-MeATP had potent vasoconstrictor activity, whereas angiotensin II had modest pressor activity. In the systemic vascular bed, the P2X-receptor agonist had modest pressor activity. In the mesenteric circulation, ␣,␤-MeATP produces a biphasic response with an initial vasoconstrictor component and a secondary vasodilator component. In the systemic vascular bed, ␣,␤-MeATP was far less potent than angiotensin II or the thromboxane A 2 mimic U-46619 in increasing vascular resistance. Pressor responses to ␣,␤-MeATP are antagonized in a selective manner by the P2X-receptor antagonist PPADS in the mesenteric and hindquarter vascular bed. Responses to ␣,␤-MeATP were not altered by meclofenamate, phentolamine, or AT 1 -receptor blocking agents, suggesting that the release of cyclooxygenase products and the activation of ␣-adrenergic or AT 1 receptors are not involved in mediating or modulating responses in the mesenteric and hindquarter circulation. The results of the present studies in the systemic vascular bed and previous studies in the pulmonary vascular bed of the cat are consistent with the hypothesis that ␣,␤-MeATP induces vasoconstriction by directly activating a PPADS-sensitive P2X receptor and that the P2X-receptor density or distribution may differ in different regional vascular beds.
